Steve Schonfeld’s Centessa Pharmaceuticals CNTA Stock Holding History

Steve Schonfeld’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-171,933	Closed	-$6.83M	–	2667
2026 Q1	$6.83M	Buy	+171,933	New	+$4.4M	0.05%	401
2025 Q4	–	Sell	-172,696	Closed	-$4.19M	–	2121
2025 Q3	$4.19M	Buy	172,696 +54,533	+46%	+$969K	0.02%	665
2025 Q2	$1.55M	Sell	118,163 -159,407	-57%	-$2.02M	0.01%	1109
2025 Q1	$3.99M	Sell	277,570 -87,630	-24%	-$1.43M	0.02%	613
2024 Q4	$6.12M	Buy	+365,200	New	+$6.05M	0.04%	433
2024 Q3	–	Sell	-12,300	Closed	-$111K	–	2092
2024 Q2	$111K	Buy	+12,300	New	+$117K	﹤0.01%	1878
2024 Q1	–	Sell	-12,629	Closed	-$101K	–	2114
2023 Q4	$101K	Buy	+12,629	New	+$84.7K	﹤0.01%	1620

Steve Schonfeld's CNTA Position: Q2 2026 in Review

Steve Schonfeld sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 171,933 shares — an estimated $6.83M sold.

Steve Schonfeld first reported a position in CNTA in Q4 2023 and held it in 7 quarters. The position peaked at $6.83M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Steve Schonfeld reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 171,933 Centessa Pharmaceuticals shares in Q2 2026, an estimated $6.83M.
Steve Schonfeld first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Steve Schonfeld's Centessa Pharmaceuticals position peaked at $6.83M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.